Shengxiang Biotech (688289.SH) plans to establish a new joint venture with the Industrial Fund to focus on the field of rapid drug sensitivity testing

Shengxiang Biology (688289.SH) announced that the company intends to partner with the relevant party Hunan Xiangjiang Shengxiang Biological Industry Fund...

Zhitong FinanceMay 8 08:32 ET

Shengxiang Biology (688289.SH): Plans to invest in Hunan Shengwei Sumin with related parties and transfer shares in the participating company FirstLight

On May 8, Ge Longhui Biotech (688289.SH) announced that it plans to jointly invest in the joint venture Hunan Shengwei Sumin Biotechnology Co., Ltd. (“Hunan Shengwei Sumin”) with the related party Hunan Xiangjiang Shengxiang Biological Industry Fund (limited partnership), of which the company's total investment amount is RMB 53.33 million. At the same time, the company plans to transfer 21.69% of the shares in the participating company FirstLightDiagnostics, Inc. (“FirstLight”) to a wholly-owned subsidiary of the joint venture with a consideration of 2,215,8

Gelonghui FinanceMay 8 07:41 ET

Sansure Biotech's (SHSE:688289) Earnings Quality Is Low

After announcing weak earnings, Sansure Biotech Inc.'s (SHSE:688289) stock was strong. Despite the strength in the stock, we feel that investors should be cautious about some numbers in the earnings.

Simply Wall StMay 6 23:55 ET

Sansure Biotech Inc.'s (SHSE:688289) Shares May Have Run Too Fast Too Soon

Sansure Biotech Inc.'s (SHSE:688289) price-to-sales (or "P/S") ratio of 10.8x might make it look like a strong sell right now compared to the Medical Equipment industry in China, where around half of

Simply Wall StApr 26 20:14 ET

Shengxiang Biotech (688289.SH): Net profit of 81.025 million yuan in the first quarter increased 35.01% year-on-year

On April 26, Ge Longhui (688289.SH) released its report for the first quarter of 2024, achieving operating income of 391 million yuan, an increase of 100.31%; net profit attributable to shareholders of listed companies of 81.025 million yuan, an increase of 35.01% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss of 73.755 million yuan, an increase of 1962.06% year on year; basic earnings per share of 0.14 yuan.

Gelonghui FinanceApr 26 10:24 ET

Shengxiang Biotech (688289.SH) posted an advance increase. The net profit for the first quarter is expected to be 81.4891 million yuan, an increase of 35.79% over the previous year

Shengxiang Biotech (688289.SH) announced that the company expects to become a parent company in the first quarter of 2024...

Zhitong FinanceApr 12 04:23 ET